Radek Sýkora

Radek Sýkora

Auto-generated profile, based on publicly available information

Radek Sýkora

Department of Urology, University Hospital, Ostrava, Czech Republic

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2018 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
JKJan Krhut
Jan Krhut
VBVladimír Borovička
Vladimír Borovička
KBKarolína Bílková
Karolína Bílková
RSRadek Sýkora
Radek Sýkora
DMDavid Míka
David Míka
RZRoman Zachoval
Roman Zachoval

3 December 2015 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
PDF file
JKJan Krhut
Jan Krhut
MNMarie Navratilova
Marie Navratilova
RSRadek Sykora
Radek Sykora
MJMichaela Jurakova
Michaela Jurakova
MGMarcel Gärtner
Marcel Gärtner
PZPeter Zvara
Peter Zvara
Objective. It was hypothesized that increasing the time for which onabotulinum toxin A (OnabotA) is exposed to the urothelium following intravesical instillation will augment its effect. TC-3 is an inert heat-sensitive hydrogel, which creates an intravesical bulk providing a slow release of the embedded drug after instillation. The aim of this study was to evaluate the effect of OnabotA, embedded in inert TC-3 hydrogel, in patients with idiopathic overactive bladder (OAB). Methods. In total, 39 female patients (age 30–65, average 53.8 years) with OAB symptoms were randomized for the study into four groups, each receiving 50 ml of the following intravesical instillations: Group A, 0.9% NaCl (placebo, n = 11); Group B, TC-3 gel + 200 U OnabotA (n = 9); Group C, TC-3 gel + 200 U OnabotA + dimethyl sulfoxide (DMSO) (n = 10); and Group D, DMSO (n = 9). The parameters were compared before and 1 month after treatment. Results. When comparing parameters using conventional statistical methods (Kruskal–Wallis test), no statistically significant changes were observed within the groups. Comparison of the medians using an analysis based on the mathematical gnostics showed the superiority of the method used in Group B over the other groups in the following parameters: number of urgency grade 3 + 4 episodes/72 h, number of leakage episodes/72 h, Overactive Bladder Questionnaire total score and Patient Perception of Bladder Condition total score. Group D showed its superiority over the other groups in respect to the number of nocturia episodes/72 h. Conclusions. The results indicate that intravesical instillation of OnabotA, embedded in TC-3 gel, could become an alternative to intramural injection for a well-selected subgroup of patients.

18 May 2015 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
JKJan Krhut
Jan Krhut
MGMarcel Gärtner
Marcel Gärtner
RSRadek Sýkora
Radek Sýkora
PHPetr Hurtik
Petr Hurtik
MBMichal Burda
Michal Burda
PZPeter Zvara
Peter Zvara

22 July 2013 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
JKJan Krhut
Jan Krhut
MGMarcel Gärtner
Marcel Gärtner
MPMartin Petzel
Martin Petzel
RSRadek Sykora
Radek Sykora
DNDavid Nemec
David Nemec
JSJana Skoupa
Jana Skoupa
The aim of this study was to evaluate the persistence of first line anticholinergic medication use by patients with overactive bladder (OAB). Data from a hospital outpatient database were matched with information obtained by a telephone survey of patients to determine which patients discontinued use of anticholinergic medication and to identify the reasons underlying discontinuation. The study group included 377 OAB patients (52 men, 325 women) with a mean age of 60.29 ± 13.84 years. In total, 189 patients (50.1%) were treated with trospium (median dose 27.86 ± 12.73 mg), 41 patients (10.9%) with propiverine (28.17 ± 4.97 mg), nine patients (2.4%) with extended-release tolterodine (4.0 ± 0 mg), 48 patients (12.7%) with solifenacin (5.94 ± 1.97 mg) and 90 patients (23.9%) with fesoterodine (6.09 ± 2.01 mg). The median time for persistence with the first line anticholinergic treatment was 6.53 ± 3.84 months. Persistence was significantly higher in patients treated with anticholinergic medication with an extended-release formulation than in patients treated with immediate-release anticholinergics. The most common reasons for termination of treatment were healing/resolution of symptoms (35.9%), low effectiveness (30.9%) and side-effects (23.7%). More than half of the OAB patients were not satisfied with their first line treatment. Other treatment options should be sought, such as changing the medication or dosage, or possibly combining treatments.

14 November 2011 in Videosurgery and Other Miniinvasive Techniques
Verified
Journal Article
Open access
RSRadek Sýkora
Radek Sýkora
JKJan Krhut
Jan Krhut
TJTomáš Jonszta
Tomáš Jonszta
DNDavid Němec
David Němec
OHOndřej Havránek
Ondřej Havránek
LMLubomir Martinek
Lubomir Martinek
Laparoscopic surgery has become a frequently used modality for rectal tumour surgery. A fistula between the rectum and lower urinary tract is one of the possible complications, with rectovesical fistulas occurring most frequently. This case report presents a 66-year-old man who underwent a...

24 February 2018 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
LLLibor Lunacek
Libor Lunacek
MGMarcel Gärtner
Marcel Gärtner
JKJan Krhut
Jan Krhut
DMDavid Mika
David Mika
RSRadek Sykora
Radek Sykora
PZPeter Zvara
Peter Zvara